- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04403165
Fonction du locus coeruleus chez les personnes âgées normales et le risque de MA (LEAD)
Growing evidence suggests that Alzheimer's disease (AD) pathological changes begin decades before clinical symptoms and tau abnormalities in the locus coeruleus (LC) can be observed since midlife. We have previously demonstrated functional vulnerability of the LC to aging and stress, as well as an association between higher cerebrospinal fluid (CSF) tau and impaired sleep phenomena influenced by the LC. We now aim to test whether LC dysfunction can be measured in preclinical AD stages by LC targeted imaging, and whether it objectively affects sleep architecture and attention. We will test this hypothesis in 30 cognitively normal older adults by performing a full clinical evaluation, one night of polysomnography, a lumbar puncture to obtain cerebrospinal fluid, [11C]MRB PET-MR, and attention testing. This study has the potential to identify a new mechanism by which tau pathology contributes to sleep and attention dysfunction and may provide a new therapeutic target for AD prevention.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The purpose of this study is three-fold: to test whether lower NET availability in the LC is associated with: first, CSF tau levels typical of preclinical stages of AD (Aim 1); second, reduced REM and spindle density (Aim 2); and third, impaired performance on attention tasks (Aim 3). The goal is to test the overarching hypothesis that LC dysfunction occurs in preclinical AD stages, can be measured with MRB-PET, and translates into impairment of sleep architecture (LC tonic dysfunction) and attention (LC phasic dysfunction).
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
New York
-
New York, New York, États-Unis, 10029
- Icahn School of Medicine Mount Sinai
-
New York, New York, États-Unis, 10016
- NYU Grossman School of Medicine
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male and female subjects with normal cognition and 55-75 years of age will be enrolled.
- Subjects will be within normal limits on neurological and psychiatric examinations.
- All subjects enrolled will have a CDR of 0. This will be evaluated through a clinical interview administered by a study physician (informant interview will not be required).
- All subjects will have had a minimum of 12 years of education.
Exclusion Criteria:
- History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, stroke, mental retardation or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders).
- Significant history of alcoholism or drug abuse.
- Significant history of psychiatric illness (e.g., schizophrenia, bipolar, PTSD, or life-long history of major depression).
- Geriatric Depression Scale (short form)>6.
- Insulin dependent diabetes.
- Evidence of clinically relevant cardiac, pulmonary, endocrine or hematological conditions.
- Physical impairment of such severity as to adversely affect the validity of psychological testing.
- Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging.
- History of a first-degree family member with early onset (age <60 years) dementia.
- Irregular sleep-wake rhythms (based on the actigraphy recordings) or significant OSA (AHI4%≥15).
- Taking Coumadin/warfarin and/or medications affecting cognition or sleep.
- Failure to complete all study visit within 4 months
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Personnes âgées cognitivement normales (NC)
|
Nocturnal polysomnography (NPSG) to measure REM sleep and sleep spindles characteristics. Lumbar puncture (LP) to measure CSF P-Tau, T-Tau and Aβ42/40 ratio. PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]O-methylreboxetine ([11C]MRB) to measure NET availability. Psychomotor vigilance task (PVT) and the OddBall to measure test taskattention performance. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Methylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) Values
Délai: Visit 4 (1-4 weeks after LP that occurred on day 14)
|
Visit 4 (1-4 weeks after LP that occurred on day 14)
|
|
|
Total Rapid Eye Movement (REM) Duration (Min)
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Percentage of Time Spent in REM Sleep
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Percentage of REM Runs That Are Less Than 5 Minutes
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
|
Percentage of REM Runs That Are Greater Than or Equal to 5 Minutes
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
|
Percentage of REM Runs That Are Greater Than or Equal to 10 Minutes
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
|
Percentage of Correct Responses on the Picture Test
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Number of Sleep Spindles That Occur Per Minute During the N2 Stage of Sleep (N2 Spindle Density)
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
N2 Spindle Density is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Mean Psychomotor Vigilance Test (PVT) Reaction Time
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
PVT measures the reaction speed to a randomly time-occuring visual stimuli, allowing the assessment of several aspects of attention including response times, attention lapses and false starts. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Picture Test Response Time
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Levels of Hyperphosphorylated Tau (P-Tau)
Délai: Visit 4 (1-4 weeks after LP that occurred on day 14)
|
Levels will be derived from the plasma and reported in pg/mL |
Visit 4 (1-4 weeks after LP that occurred on day 14)
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Ricardo Osorio, NYU Langone Health
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Les troubles mentaux
- Troubles neurocognitifs
- Démence
- Tauopathies
- Maladies neurodégénératives
- Maladie d'Alzheimer
- Techniques d'investigation
- Thérapeutique
- Manipulation des échantillons
- Techniques de laboratoire clinique
- Techniques et procédures de diagnostic
- Diagnostic
- Perforation
- Procédures chirurgicales, opératoires
- Biopsie
- Techniques de diagnostic, neurologique
- Perforation vertébrale
Autres numéros d'identification d'étude
- 20-00002
- 1R21AG067549-01 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
All of the individual participant data collected during the trial, after deidentification.
Délai de partage IPD
Immediately following publication. No end date.
Critères d'accès au partage IPD
The investigator who proposed to use the ricardo.osorio@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .